The inference of transcriptional networks that regulate transitions into physiological or pathological cellular states remains a central challenge in systems biology. A mesenchymal phenotype is the hallmark of tumour aggressiveness in human malignant glioma, but the regulatory programs responsible for implementing the associated molecular signature are largely unknown. Here we show that reverse-engineering and an unbiased interrogation of a glioma-specific regulatory network reveal the transcriptional module that activates expression of mesenchymal genes in malignant glioma. Two transcription factors (C/EBPb and STAT3) emerge as synergistic initiators and master regulators of mesenchymal transformation. Ectopic co-expression of C/EBPb and STAT3 reprograms neural stem cells along the aberrant mesenchymal lineage, whereas elimination of the two factors in glioma cells leads to collapse of the mesenchymal signature and reduces tumour aggressiveness. In human glioma, expression of C/EBPb and STAT3 correlates with mesenchymal differentiation and predicts poor clinical outcome. These results show that the activation of a small regulatory module is necessary and sufficient to initiate and maintain an aberrant phenotypic state in cancer cells.
determine directed (that is, causal) interactions 12, 22 (see Methods) . ARACNe predicted 92,660 transcriptional interactions, 1,217 of which were between TFs and 102 out of 149 MGES genes 4 , represented across all the gene expression profile data.
Next, we applied a new master regulator analysis (MRA) algorithm to the HGG-interactome. The algorithm computes the statistical significance of the overlap between the regulon of each TF (that is, its ARACNe-inferred targets) and the MGES genes (P values computed by Fisher's exact test, FET). From a list of 928 TFs (Supplementary  Table 2 ), MRA inferred 53 MGES-specific TFs, at a false discovery rate (FDR) , 5% ( Supplementary Table 3a ). These were ranked on the basis of the total number of MGES targets they regulated. The top six TFs (STAT3, C/EBP, bHLH-B2 (also known as bHLHE40), RUNX1, FOSL2 and ZNF238) collectively controlled .74% of the MGES genes ( Fig. 1a ). C/EBPb and C/EBPd were grouped as they form stoichiometric homo-and heterodimers with identical DNA-binding specificity and redundant transcriptional activity 23 . We thus use the term C/EBP to indicate the TF complex with the union of their targets as the corresponding regulon. Consistent with their previously reported activity 24, 25 , Spearman's correlation analysis showed that five of these TFs are probably activators (STAT3, C/EBP, bHLH-B2, RUNX1 and FOSL2) and one is probably a repressor (ZNF238). a, TFs involved in activation of MGES targets are shown in pink, those involved in repression are in purple. MGES targets controlled by these TFs are in cyan. Overall, the six TFs control 74% of the genes in the mesenchymal signature of high-grade glioma. A region between 2 kb upstream and downstream the transcription start site of the target genes identified by ARACNe was analysed for the presence of putative binding sites.
b-e, Genomic regions of genes containing putative binding sites for specific TFs were immunoprecipitated in SNB75 cells by antibodies specific for STAT3 (b), C/EBPb (c), FOSL2 (d), and bHLH-B2 (e). SOCS3 was included as positive control of STAT3 binding. Total chromatin before immunoprecipitation was used as positive control for PCR. The OLR1 gene was used as negative control. f, Summary of binding results of the tested TFs to mesenchymal targets.
Overlap between the regulons of these TFs was highly significant (Supplementary Table 4 ). MRA of the PNGES and Proliferative (PROGES) signatures of HGGs detected virtually no overlap among candidate MRs of the three signatures, with the notable exception of few TFs inversely associated with MGES and PNGES activation ( Supplementary Table 5 ). Next, we used stepwise linear regression to determine simple, quantitative regulation models for each MGES gene. Specifically, the log-expression of each MGES gene was fitted by the linear combination of the log-expression of a small number of genes (1-5; see Methods), selected among 53 ARACNe-inferred and 52 additional TFs, whose DNA-binding signatures were enriched in the promoters of MGES genes. Six TFs were in both lists, for a total of 99 TFs ( Supplementary Table 3b ). TFs were then ranked on the basis of the fraction of MGES genes they regulated. Surprisingly, the top six MRA-inferred TFs were also among the eight controlling the largest number of MGES targets, based on stepwise linear regression analysis ( Supplementary Table 6 ). Indeed, the three with the highest linearregression coefficient values were C/EBP (a 5 0.40), bHLH-B2 (a 5 0.41) and STAT3 (a 5 0.40), further establishing them as probable MGES-MR candidates. The next strongest TF, ZNF238, had a negative coefficient (a 5 20.34) confirming its role as a candidate MGES repressor.
Validation of the mesenchymal regulatory module
To determine whether these TFs bind the promoter region of their predicted MGES targets, we performed chromatin immunoprecipitation (ChIP) in a human glioma cell line. On average, TF-specific antibodies but not control antibodies immunoprecipitated 80% of the tested genomic regions ( Fig. 1b-f ). Lentivirus-mediated short hairpin RNA (shRNA) silencing of CEBPB, STAT3, bHLH-B2, FOSL2 and RUNX1 in glioma cells, followed by gene expression profiling and Gene Set Enrichment Analysis (GSEA), showed that after silencing of each TF, differentially expressed genes were highly enriched in their ARACNe-inferred targets but not in those of control TFs with equivalent regulon size ( Supplementary Table 7a ). Furthermore, differentially expressed genes were also enriched in MGES genes ( Supplementary Table 7b ).
Promoter occupancy analysis revealed a hierarchical and highly modular topology, with eight out of ten possible intra-module interactions implemented (modularity P 5 1.0 3 10 28 by FET, Fig. 2c ). Specifically, CEBPb and STAT3 occupy their own promoter ( Fig. 2a , b); C/EBPb occupies the STAT3, FOSL2, bHLH-B2, CEBPB and CEBPD promoters ( Fig. 2a ); STAT3 occupies those of FOSL2 and RUNX1 (Fig. 2b) ; FOSL2 occupies those of RUNX1 and bHLH-B2 ( Supplementary Fig. 3a ), and bHLH-B2 only occupies the RUNX1 promoter ( Supplementary Fig. 3b ). C/EBP and STAT3 are at the top of this hierarchical regulatory module. They have autoregulatory loops and form feed-forward loops with a larger fraction of MGES genes (43%) than any of the other TF pairs. shRNA-mediated cosilencing of C/EBPb and STAT3 in glioma cells produced .2-fold reduction of the messenger RNAs coding for the second layer TFs in the feed-forward loops (bHLH-B2, FOSL2 and RUNX1; Fig. 2d ), supporting their role as MRs. C/EBPb and STAT3 also bound the promoters of their MGES targets in primary human GBM (Supplementary Fig. 3c, d) .
To validate functionally the role of C/EBPb and STAT3 as MRs of the MGES, we conducted gain-and loss-of-function experiments. We transduced v-myc immortalized mouse NSCs (mNSCs) known as C17. 2 (refs 26-28) , as well as primary mNSCs derived from the mouse telencephalon at embryonic day (E)13.5, with retroviruses expressing C/EBPb and a constitutively active form of STAT3 (STAT3C) 29 . shRNA-mediated silencing targeted C/EBPb and STAT3 in the human glioma cell line SNB19, and in serum-free cultures of tumour cells derived from primary GBM that propel the formation of GBM-like tumours after intracranial transplantation in immunodeficient mice 30 (GBM-derived brain tumour initiating cells, GBM-BTICs; see later).
We generated a global data set of 89 individual samples, including 55 knockdown experiments in human glioma cells and 34 ectopic expression experiments in mouse NSCs. Of the 149 genes in the MGES, 118 could be mapped to murine genes represented on the array ( Supplementary Table 8 ). Quantitative PCR with reverse transcription (qRT-PCR) analysis showed that, after CEBPB or STAT3 shRNA silencing in GBM-BTICs and SNB19 cells, the corresponding mRNA levels were significantly reduced compared to non-target control transduced cells (CEBPB fold ratio 5 0.26, P # 0.00108, STAT3 fold ratio 5 0.205, P # 0.00109 by U-test). Reciprocal changes followed ectopic expression of the two TFs in C17.2 cells and NSCs (Supplementary Table 9 ). qRT-PCR values and microarray-based measurements were highly correlated for STAT3 but not for CEBPB mRNA ( Supplementary Fig. 4 ). Thus, we used the qRT-PCR values for CEBPB and STAT3 as more accurate read-outs for their mRNA expression. GSEA confirmed that genes co-expressed with the two TFs . Samples (columns) were grouped according to species and treatment. Control, control shRNA or empty vector; S2, STAT3 knockdown; S1, STAT3 overexpression; C2, CEBPB knockdown; C1, CEBPB overexpression; S2/ C2, STAT3 and CEBPB knockdown; S1/C1, STAT3 and CEBPB overexpression. g, GSEA of the MGES on the gene expression profile ranksorted according to the correlation with the CEBPB 3 STAT3 metagene. The bar-code plot indicates the position of MGES genes, red and blue colours represent positive and negative correlation, respectively. The grey scale bar indicates the Spearman's rho coefficient used as weighting score for GSEA. LEOR, leading-edge odds ratio; nES, normalized enrichment score; P, sample-permutation-based P value.
were enriched in their respective ARACNe-inferred regulon genes but not in those of control TFs (Supplementary Table 10 ). Perturbation of C/EBPb ( Supplementary Fig. 5a , c) or STAT3 ( Supplementary Fig. 5b , d) specifically affected the MGES signature (P 5 2.69 3 10 22 and P 5 2.0 3 10 24 , respectively, by GSEA). Common targets of C/EBP and STAT3 were eightfold more enriched in MGES genes than targets controlled individually by each TF ( Fig. 2e , P 5 2.25 3 10 25 ). To test whether the two TFs may be involved in synergistic MGES control, we computed a metagene (CEBPB 3 STAT3) with expression proportional to the product of their mRNAs, such that the metagene should be highly correlated with the expression profile of any target synergistically regulated by the two TFs, under a multiplicative model ( Fig. 2f ). GSEA confirmed that genes ranked by Spearman's correlation to the CEBPB 3 STAT3 metagene were significantly enriched in MGES genes ( Fig. 2g ), suggesting that at least a subset of the MGES is synergistically regulated by the CEBPB 3 STAT3 pair. We sought to establish (1) whether MRs inferred by our procedure would also be inferred when using an independent glioma sample data set, and (2) whether MRs identified on the basis of clinical outcome would overlap significantly with those inferred from MGES analysis. The Atlas-TCGA data set 31 includes 77 and 21 samples associated with worst-and best-prognosis, respectively (92 samples with intermediate prognosis were not considered). Differential expression analysis identified a TCGA worst-prognosis signature (TWPS), comprising 884 genes differentially expressed in the worst-prognosis versus bestprognosis samples (at P # 0.05 by Student's t-test, Supplementary  Table 11 ). GSEA confirmed that MGES genes were markedly enriched in the TWPS signature (P # 1.0 3 10 24 , Supplementary Fig. 6 ) indicating that the poor-prognosis group in the Atlas-TCGA data set displays marked mesenchymal features. Despite partial overlap between MGES and TWPS genes (22.8%), five of the six MRs identified by MRA from the original data set were also found among the ten most significant TFs identified by MRA of the Atlas-TCGA data set using the TWPS signature. C/EBP was the most significant TF, and STAT3 was in seventh position. C/EBPb and C/EBPd had the first and second best linear-regression coefficient by stepwise linear regression analysis, respectively ( Supplementary Table 12 ). These results indicate significant robustness of the approach both to data set and signature selection.
Mesenchymal reprogramming of NSCs by C/EBPb and STAT3
We tested whether combined and/or individual expression of STAT3C and C/EBPb in NSCs is sufficient to trigger the mesenchymal phenotype that characterizes HGGs. The introduction of C/EBPb and STAT3C into C17.2 NSCs caused loss of neuronal differentiation and manifestation of a fibroblast-like morphology ( Supplementary  Fig. 7a, b ). The morphological changes were associated with gain of expression of the mesenchymal marker proteins smooth muscle alpha actin (SMA, encoded by Acta2) and fibronectin ( Fig. 3a and Supplementary Fig. 7c, d) , and with induced expression of the mesenchymal genes Chi3l1 (also known as Ykl40), Acta2, Ctgf and Osmr (Fig. 3b ). The individual expression of STAT3C or C/EBPb was generally insufficient to induce expression of either mesenchymal marker proteins or mesenchymal genes ( Fig. 3a, b ). Removal of mitogens to STAT3C plus C/EBPb-expressing C17.2 cells resulted in a further increase in the expression of mesenchymal genes, and complete acquisition of mesenchymal properties such as positive alcian blue staining, a specific assay for chondrocyte differentiation ( Fig. 3c and Supplementary Fig. 7e, f) . The expression of STAT3C and C/EBPb promoted migration in a wound assay, and triggered invasion through the extracellular matrix in a Matrigel invasion assay in the absence or presence of PDGF (Fig. 3d, e and Supplementary Fig. 7g ). The combined but not individual expression of STAT3C and C/EBPb efficiently induced mesenchymal marker proteins and mesenchymal gene expression in primary NSCs (Fig. 3f-h) . Conversely, STAT3C and C/EBPb abolished differentiation along the neuronal and glial lineages ( Fig. 3i and Supplementary Fig. 7h ). The C/EBPb-and STAT3C-induced mesenchymal transformation of primary NSCs was associated with withdrawal from the cell cycle (data not shown). Thus, the combined introduction of C/EBPb and STAT3C in NSCs prevents neural differentiation and triggers reprogramming towards an aberrant mesenchymal lineage.
Mesenchymal aggressiveness of glioma by C/EBPb and STAT3
Transduction of GBM-BTIC cultures derived from two GBM patients (BTSC-20 and BTSC-3408) with specific shRNA-carrying lentiviruses silenced endogenous C/EBPb and STAT3, eliminated expression of mesenchymal genes, and depleted the tumour cells of the mesenchymal marker proteins fibronectin, collagen-5a1 and YKL40. Individual silencing of C/EBPb or STAT3 produced variable inhibitory effects, with the silencing of C/EBPb typically carrying the most severe consequences (Fig. 4a-e and Supplementary Fig. 8a ). Combined or individual silencing of C/EBPb and STAT3 in the human glioma cell line SNB19 produced similar effects (Supplementary Fig. 8b-e ). Silencing of the two TFs in SNB19 cells and GBM-BTICs reduced their ability to invade through Matrigel by .70% (Fig. 4f-i ). Next, we determined the effect of CEBPB and STAT3 knockdown on brain tumorigenesis after intracranial injection of SNB19 cells in immunocompromised mice. We observed efficient tumour formation in all mice injected with control or STAT3 shRNA cells. However, only one of four mice from the CEBPB shRNA and one of five mice from the combined CEBPB and STAT3 shRNA groups developed tumours 120 days after the injection (Fig. 5b) . The histological analysis demonstrated highgrade tumours, which displayed peripheral invasion of the surrounding brain as single cells and cell clusters in the shRNA control group, as shown by anti-human vimentin staining (Fig. 5a ). Staining for the endothelial marker CD31 revealed marked vascularization in the control shRNA tumour group. Conversely, the single tumour in the CEBPB plus STAT3 shRNA group grew well circumscribed and was less angiogenic. Tumours in the STAT3 shRNA group and the single tumour in the CEBPB shRNA group had an intermediate growth pattern and limited angiogenesis. Staining for fibronectin, collagen-5a1 and YKL40 was readily detected in the tumours from the control group but absent or barely detectable in the single tumours from the CEBPB shRNA and CEBPB plus STAT3 shRNA groups (Fig. 5a ). Tumours derived from Stat3 shRNA cells showed an intermediate phenotype, with reduced expression of mesenchymal markers compared with tumours in the control shRNA group, but higher than that observed in the tumours in the CEBPB shRNA and CEBPB plus STAT3 shRNA groups (control shRNA . STAT3 shRNA . CEBPB shRNA . CEBPB1STAT3 shRNA). Intracranial transplantation of GBM-BTICs transduced with control shRNA lentivirus produced extremely invasive tumour cell masses extending through the corpus callosum to the contralateral brain. Combined knockdown of CEBPB and STAT3 led to a significant decrease in the tumour area and tumour cell density (as evaluated by human vimentin staining), markedly reduced the proliferation index ( Fig. 5c-e ), and abolished expression of the mesenchymal markers fibronectin and collagen-5a1 ( Fig. 5f, g) . Finally, we conducted immunohistochemical analysis for C/EBPb and active, phospho-STAT3 in human tumour specimens, and compared their expression with that of YKL40 (a well-established mesenchymal protein expressed in primary human GBM) 21, 32 and with patient outcome in a collection of 62 GBM ( Supplementary  Fig. 9 ). Expression of either C/EBPb or STAT3 was significantly associated with YKL40 expression (C/EBPb, P 5 4.9 3 10 25 ; STAT3, P 5 2.2 3 10 24 ), with higher association in double-positive tumours (C/EBPb 1 STAT3 1 , P 5 2.7 3 10 26 ) versus double-negative ones (C/EBPb 2 STAT3 2 , Supplementary Table 13 ). Double-positive tumours were associated with worse clinical outcome than either single-or double-negative tumours (log-rank test, P 5 0.0002, Fig. 5h ). Positivity for either of the two TFs remained predictive of negative outcome but with lower statistical strength than double positivity (C/EBPb, P 5 0.0022; STAT3, P 5 0.0017).
Discussion
We have shown that inference of context-specific regulatory network identifies the transcriptional module that controls expression of the mesenchymal signature associated with poor prognosis in HGGs. In this approach, the traditional model of gene-expression-profilebased cancer research, yielding long lists of differentially expressed genes (that is, cancer signatures), becomes only a starting point for a cellular-network analysis, where a causal regulatory model identifies the TFs controlling the signatures and related phenotypes. Recently, there have been several unsuccessful attempts to identify common expression signatures predictive of the same cellular phenotype 33 . Our approach produced virtually identical regulatory MR modules when applied to two completely distinct data sets and signatures associated with poor prognosis in HGGs, thus indicating that MRs of mammalian phenotype signatures may be significantly more conserved than the complement of differentially expressed genes. Other methods, including differential expression analysis, DNA-binding-site enrichment analysis 8 and relevance network analysis 34 could not identify C/EBPb and STAT3 as MRs (see Supplementary Note 2). This suggests that enrichment analysis of ARACNe-inferred TF regulons is specifically useful for the identification of MRs of cellular phenotypes. Our results do not exclude that other graph-theoretical methods such as Bayesian networks might provide further fine-grain regulatory insight once the number of candidate MRs is reduced to a handful by methods such as those proposed here. Yet, once a relatively small number of TFs is identified, direct experimental validation is feasible. The experimental follow-up established that C/EBPb and STAT3 are MRs sufficient in NSCs and necessary in human glioma cells for mesenchymal transformation. Interestingly, C/EBPb and STAT3 are expressed in the developing nervous system [35] [36] [37] [38] . However, although STAT3 induces astrocyte differentiation and inhibits neuronal differentiation of neural stem/progenitor cells, C/EBPb promotes neurogenesis and opposes gliogenesis [39] [40] [41] . A question remains as to how the combined activity of C/EBPb and STAT3 can reprogram NSCs towards an aberrant lineage (mesenchymal) and oppose the genesis of the normal neural lineages (neuronal and glial). We propose that mesenchymal transformation results from the concurrent activation of two conflicting transcriptional regulators normally operating to funnel opposing signals (neurogenesis versus gliogenesis). This condition is intolerable by normal neural stem/progenitor cells, whereas it operates to permanently drive the aberrant mesenchymal phenotype in the context of the genetic and epigenetic changes that accompany highgrade gliomagenesis (for example, EGFR amplification, PTEN loss, Akt activation) 4 . Because expression of C/EBPb and STAT3 in human glioma is essential to maintain the tumour initiating capacity and the ability to invade the normal brain, the two TFs provide important clues for diagnostic and pharmacological intervention. Consistent with this, the combined expression of C/EBPb and STAT3 is linked to the mesenchymal state of primary GBM, and provides an excellent prognostic biomarker for tumour aggressiveness.
Thus, systems biology methods can be effectively used to infer MRs that choreograph malignant transformation. This model will be applicable to the dissection of other phenotypic states.
METHODS SUMMARY
Cell culture. Primary NSCs were isolated from E13.5 mouse telencephalon, and cultured in the presence of FGF2 and EGF as described 42 . Differentiation was induced by culturing NSCs in NSC medium without EGF and FGF2. GBMderived BTICs were grown in Neurobasal media supplemented with FGF2 and EGF. Generation of transcriptional network, microarrays and qRT-PCR. GBM transcriptional network was generated by ARACNe 12 . Total RNA was reverse transcribed to complementary DNA and amplified using primers specific for human and murine transcripts. Expression values were calculated relative to the 18S ribosomal RNA. RNA was used for analysis on Illumina HumanHT-12v3 or MouseWG-6 expression BeadChip. Sample information is in Methods. Master regulator analysis. For each TF, the statistical significance of the intersection between the TF-regulon and the gene expression signature was computed by FET. Significant genes were ranked on the basis of the number of overlapping genes. GSEA. The statistical significance of the enrichment of a ranked list of genes in a smaller set of genes was determined as described 43 .
Stepwise linear regression. The regulatory model of each gene was determined by identifying the smallest number of TFs that were informative for the expression of that gene across the data set. TFs were added to the model one at the time, until the error reduction produced by adding another TF was no longer statistically significant. Models had on average 1-5 TFs. Intracranial injection of glioma cells. SNB19 glioma cell line and GBM-derived BTICs were injected into the brain of 6-8 weeks NOD/SCID mice 48 h after infection with lentiviruses carrying shRNAs using a stereotaxic frame. Animals were monitored and euthanized when they presented with signs of tumour.
Mouse research was approved by the Committee for Animal Care, and conducted in compliance with the Animal Welfare Act Regulations.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
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